These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31884896)

  • 1. Idelalisib induces apoptosis in the lymphoid tissues and impairs lung function in mice.
    George JA; Alshebli Z; Alneyadi A; Al Mukhaini N; Al-Salam S; Sudhadevi M; Souid AK; Alsuwaidi AR
    J Chemother; 2020 Apr; 32(2):88-97. PubMed ID: 31884896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
    Chellappa S; Kushekhar K; Munthe LA; Tjønnfjord GE; Aandahl EM; Okkenhaug K; Taskén K
    J Immunol; 2019 Mar; 202(5):1397-1405. PubMed ID: 30692213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.
    Rohrbacher L; Brauchle B; Ogrinc Wagner A; von Bergwelt-Baildon M; Bücklein VL; Subklewe M
    Front Immunol; 2021; 12():608625. PubMed ID: 33790890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idelalisib.
    Zirlik K; Veelken H
    Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies.
    Kim YS; Cheon MG; Boggu PR; Koh SY; Park GM; Kim G; Park SH; Park SL; Lee CW; Kim JW; Jung YH
    Bioorg Med Chem; 2021 Sep; 45():116312. PubMed ID: 34332211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
    Stock S; Übelhart R; Schubert ML; Fan F; He B; Hoffmann JM; Wang L; Wang S; Gong W; Neuber B; Hückelhoven-Krauss A; Gern U; Christ C; Hexel M; Schmitt A; Schmidt P; Krauss J; Jäger D; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2019 Sep; 145(5):1312-1324. PubMed ID: 30737788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idelalisib Rescues Natural Killer Cells from Monocyte-Induced Immunosuppression by Inhibiting NOX2-Derived Reactive Oxygen Species.
    Akhiani AA; Hallner A; Kiffin R; Aydin E; Werlenius O; Aurelius J; Martner A; Thorén FB; Hellstrand K
    Cancer Immunol Res; 2020 Dec; 8(12):1532-1541. PubMed ID: 32967913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
    Hanna BS; Roessner PM; Scheffold A; Jebaraj BMC; Demerdash Y; Öztürk S; Lichter P; Stilgenbauer S; Seiffert M
    Leukemia; 2019 Jun; 33(6):1427-1438. PubMed ID: 30573773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idelalisib inhibits osteoclast differentiation and pre-osteoclast migration by blocking the PI3Kδ-Akt-c-Fos/NFATc1 signaling cascade.
    Yeon JT; Kim KJ; Son YJ; Park SJ; Kim SH
    Arch Pharm Res; 2019 Aug; 42(8):712-721. PubMed ID: 31161369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase δ.
    Somoza JR; Koditek D; Villaseñor AG; Novikov N; Wong MH; Liclican A; Xing W; Lagpacan L; Wang R; Schultz BE; Papalia GA; Samuel D; Lad L; McGrath ME
    J Biol Chem; 2015 Mar; 290(13):8439-46. PubMed ID: 25631052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.
    Yang Q; Chen LS; Ha MJ; Do KA; Neelapu SS; Gandhi V
    Clin Cancer Res; 2017 Jan; 23(1):181-192. PubMed ID: 27342398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
    Lim EL; Cugliandolo FM; Rosner DR; Gyori D; Roychoudhuri R; Okkenhaug K
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of parenteral glutamine supplementation combined with enteral nutrition on Hsp90 expression and lymphoid organ apoptosis in severely burned rats.
    Fan J; Wu J; Wu LD; Li GP; Xiong M; Chen X; Meng QY
    Burns; 2016 Nov; 42(7):1494-1506. PubMed ID: 27613477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated molecular modeling techniques to reveal selective mechanisms of inhibitors to PI3Kδ with marketed Idelalisib.
    Zhu J; Jia L; Jiang Y; Yu Q; Xu L; Cai Y; Chen Y; Li H; Gang H; Liang W; Jin J
    Chem Biol Drug Des; 2021 Jun; 97(6):1158-1169. PubMed ID: 33657663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of apoptosis with fusarenon-X in mouse thymocytes.
    Miura K; Nakajima Y; Yamanaka N; Terao K; Shibato T; Ishino S
    Toxicology; 1998 May; 127(1-3):195-206. PubMed ID: 9699806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
    Chen Y; Zhou Q; Zhang L; Wang R; Jin M; Qiu Y; Kong D
    Oncol Rep; 2016 Dec; 36(6):3643-3650. PubMed ID: 27748929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib.
    Bashash D; Safaroghli-Azar A; Dadashi M; Safa M; Momeny M; Ghaffari SH
    Int J Biochem Cell Biol; 2017 Apr; 85():149-158. PubMed ID: 28254430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
    Lampson BL; Brown JR
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells.
    Braun C; Schlaweck S; Daecke SN; Brossart P; Heine A
    Cancer Immunol Immunother; 2021 Dec; 70(12):3693-3700. PubMed ID: 34173009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.